U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Kuntz K, Sainfort F, Butler M, et al. Decision and Simulation Modeling in Systematic Reviews [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb.

Cover of Decision and Simulation Modeling in Systematic Reviews

Decision and Simulation Modeling in Systematic Reviews [Internet].

Show details

References and Included Studies

1.
Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases Science. 4157. Vol. 185. 1974. pp. 1124–1131. [PubMed: 17835457]
2.
Rittenhouse B. Uses of models in economic evaluations of medicines and other health technologies. London: Office of Health Economics; 1996.
3.
Albert DA. Decision theory in medicine: a review and critique. Milbank Mem Fund Q Health Soc. 1978;56(3):362–401. [PubMed: 100721]
4.
von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. Third ed. Princeton: Princeton University Press; 1953.
5.
Ledley RS, Lusted LB. Reasoning foundations of medical diagnosis; symbolic logic, probability, and value theory aid our understanding of how physicians reason. Science. 1959;130:9–21. [PubMed: 13668531]
6.
Henschke UK, Flehinger BJ. Decision theory in cancer therapy. Cancer. 1967;20(11):1819–1826. [PubMed: 6061617]
7.
Ingelfinger FJ. Decision in medicine. N Engl J Med. 1975;293(5):254–255. [PubMed: 1143307]
8.
Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia: WB Saunders Company; 1980.
9.
Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419–458. [PubMed: 6668990]
10.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322–338. [PubMed: 8246705]
11.
Petitti DB. Methods for Quantitative Synthesis in Medicine. 2 ed. New York, NY: Oxford UP; 2000. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis.
12.
Kassirer JP, Moskowitz AJ, Lau J, et al. Decision analysis: a progress report. Ann Inter Med. 1987;106(2):275–291. [PubMed: 3541727]
13.
Russel LB. Educated Guesses: Making Policy About Medical Screening Tests. Los Angeles: University of California Press; 1994.
14.
Mulrow C, Langhorne P, Grimshaw J. Integrating heterogeneous pieces of evidence in systematic reviews. Annals of Internal Medicine. 1997 Dec 1;127(11):989–995. [PubMed: 9412305]
15.
Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Economics. 2006 Dec;15(12):1295–1310. [PubMed: 16941543]
16.
Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: The impact of herd-immunity. Med Decis Making. 2003;23(1):76–82. [PubMed: 12583457]
17.
Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases. 2007 Jan;13(1):28–41. [PMC free article: PMC2725801] [PubMed: 17370513]
18.
Jun JB, Jacobson SH, Swisher JR. Application of discrete-event simulation in health care: A survey. J Opl Res Soc. 1999;50(2):109–123.
19.
Stahl JE, Rattner D, Wiklund R, et al. Reorganizing the system of care surrounding laparoscopic surgery: A cost-effectiveness analysis using discrete-event simulation. Med Decis Making. 2004;24(5):461–471. [PubMed: 15358995]
20.
Marjamaa RA, Torkki PM, Hirvensalo EJ, et al. What is the best workflow for an operating room? A simulation study of five scenarios. Health Care Manage Sci. 2009;12(2):142–146. [PubMed: 19469453]
21.
Schwartz WB. Sounding board. Decision Analysis: a look at the chief complaints. N Engl J Med. 1979;300(10):556–559. [PubMed: 763258]
22.
Braithwaite RS, Roberts MS, Justice AC. Incorporating quality of evidence into decision analytic modeling. Ann Inter Med. 2007;146(2):133–141. [PMC free article: PMC3460380] [PubMed: 17227937]
23.
U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Am Fam Physician. 2002;66(12):2287–2290. [PubMed: 12507168]
24.
U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Inter Med. 2008 Nov 4;149(9):627–637. [Summary for patients in Ann Intern Med 2008 Nov 4;149(9):I-44; PMID: 18838719] [PubMed: 18838716]
25.
Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Inter Med. 2008;149(9):638–658. [PubMed: 18838718]
26.
Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Inter Med. 2008;149(9):659–669. [PMC free article: PMC2731975] [PubMed: 18838717]
27.
Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: Uses, roles and validity. Value Health. 2001;4(5):348–361. [PubMed: 11705125]
28.
Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics. 2000 May;17(5):461–477. [PubMed: 10977388]
29.
Bonis PA, Trikalinos TA, Chung M, et al. Hereditary Nonpolyposis Colorectal Cancer: Diagnostic Strategies and Their Implications. Evidence Report/Technology Assessment No. 150. Rockville, MD: Agency for Healthcare Research and Quality; May, 2007. (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No.290-02-0022) AHRQ Publication No. 07-E008. [PMC free article: PMC4781224] [PubMed: 17764220]
30.
Lau J, Ioannidis JP, Balk E, et al. Evaluation of Technologies for Identifying Acute Cardiac Ischemia in Emergency Departments. Evidence Report: Technology Assessment No. 26. Rockville, MD: Agency for Healthcare Research and Quality; Sep, 2000. (Prepared by The New England Medical Center Evidence-based Practice Center under Contract No. 290-97-0019) AHRQ Publication No. 01-E006. [PMC free article: PMC4780879] [PubMed: 11079073]
31.
Lau J, Zucker D, Engels EA, et al. Diagnosis and Treatment of Acute Bacterial Rhinosinusitis. Evidence Report: Technology Assessment No. 9. Rockville, MD: Agency for Healthcare Research and Quality; Mar, 1999. (Prepared by New England Medical Center Evidence-based Practice Center under Contract No. 290-97-0019) AHRQ Publication No. 99-E016.
32.
Trikalinos TA, Lau J. Obstructive Sleep Apnea-Hypopnea Syndrome: Modeling Different Diagnostic Strategies. Technology Assessment. Rockville, MD: Agency for Healthcare Research and Quality; Dec, 2007. (Prepared by Tufts-New England Evidence-based Practice Center under Contract No. 290-02-0022) [PubMed: 25473697]
33.
Matchar DB, Thakur ME, Grossman I, et al. Testing for Cytochrome P450 Polymorphisms in Adults With Nonpsychotic Depression Treated With Welective Werotonin Reuptake Inhibitors (SSRIs). Evidence Report/Technology Assessment No. 146. Rockville, MD: Agency for Healthcare Research and Quality; Jan, 2007. (Prepared by the Duke University Evidence-based Practice Center under Contract No. 290-02-0025) AHRQ Publication No. 07-E002. [PMC free article: PMC4781099] [PubMed: 17764209]
34.
Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No. 130. Rockville, MD: Agency for Healthcare Research and Quality; Feb, 2006. (Prepared by the Duke University Evidence-based Practice Center under Contract No. 290-02-0025) AHRQ Publication No. 06-E004.
35.
Myers ER, Havrilesky LJ, Kulasingam SL, et al. Genomic Tests for Ovarian Cancer Detection and Management. Evidence Report/Technology Assessment No. 145. Rockville, MD: Agency for Healthcare Research and Quality; Oct, 2006. (Prepared by the Duke University Evidence-based Practice Center under Contract No. 290-02-0025) AHRQ Publication No. 07-E001. [PMC free article: PMC4781315] [PubMed: 17764207]
36.
Shekelle P, Morton S, Atkinson S, et al. Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic {atients, and Cost-Effectiveness. Evidence Report: Technology Assessment No. 82. Rockville, MD: Agency for Healthcare Research and Quality; Jul, 2003. (Prepared by the Southern California-RAND Evidence-based Practice Center under Contract. No. 290-97-0001) AHRQ Publication No. 03-E045. [PMC free article: PMC4781559] [PubMed: 14571595]
37.
McAlister F, Ezekowitz J, Wiebe N, et al. Cardiac Resynchronization Therapy for Congestive Heart Failure. Evidence Report: Technology Assessment No. 152. Rockville, MD: Agency for Healthcare Research and Quality; (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-02-0023) AHRQ Publication No. 07-E009.
38.
Caughey AB, Sundaram V, Kaimal AJ, et al. Maternal and Neonatal Outcomes of Elective Induction of Labor. Evidence Report/Technology Assessment No. 176. Rockville, MD: Agency for Healthcare Research and Quality; Mar, 2009. (Prepared by the Stanford University-UCSF Evidence-based Practice Center under Contract No. 290-02-0017) AHRQ Publication No. 09-E005. [PMC free article: PMC4781541] [PubMed: 19408970]
39.
Chapell R, Reston J, Snyder D, et al. Management of Treatment-Resistant Epilepsy. Evidence Report: Technology Assessment No. 77. Rockville, MD: Agency for Healthcare Research and Quality; Apr, 2003. (Prepared by the ECRI Evidence-based Practice Center under Contract No. 290-97-0020) AHRQ Publication No. 03-0028. [PMC free article: PMC4781199] [PubMed: 12820535]
40.
Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment. 2004 Sep;8(36):iii–iv. ix–xi, 1–158. [PubMed: 15361314]
41.
Pignone M, Saha S, Hoerger T, et al. Challenges in systematic reviews of economic analyses. Annals of Internal Medicine. 2005 Jun 21;142(12 Pt 2):1073–1079. [PubMed: 15968032]
42.
Annemans L. Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making. Pharmacoeconomics. 2008;26(5):409–423. [PubMed: 18429657]
43.
Campbell H, Briggs A, Buxton M, et al. The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. Journal of Health Services & Research Policy. 2007 Jan;12(1):11–17. [PubMed: 17244392]
44.
Earnshaw SR, Wilson M, Mauskopf J, et al. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value in Health. 2009 Jun;12(4):507–520. [PubMed: 19900253]
45.
Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics. 2007;25(9):735–750. [PubMed: 17803333]
46.
Jones MT, Cockrum PC. A critical review of published economic modelling studies in depression. Pharmacoeconomics. 2000 Jun;17(6):555–583. [PubMed: 10977394]
47.
Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2002 Jul 16;137(2):96–104. [PubMed: 12118964]
48.
Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Institute of Medicine and National Research Council; 2005. [PubMed: 22379648]
49.
Sonnenberg F, Clarke L. personal communication. 2010.
50.
Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics. 2000 May;17(5):443–444. [PubMed: 10977386]
51.
Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355–371. [PubMed: 16605282]
52.
Tom E, Schulman KA. Mathematical models in decision analysis. Infection Control & Hospital Epidemiology. 1997 Jan;18(1):65–73. [PubMed: 9013249]
53.
Vale L, Thomas R, MacLennan G, et al. Systematic review of economic evaluations and cost analyses of guideline implementation strategies. European Journal of Health Economics. 2007 Jun;8(2):111–121. [PubMed: 17347844]
54.
Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value in Health. 2003 Jan-Feb;6(1):9–17. [see comment] [PubMed: 12535234]
55.
Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics. 2000 May;17(5):445–459. [PubMed: 10977387]
56.
Drummond MF, Iglesias CP, Cooper NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves? International Journal of Technology Assessment in Health Care. 2008;24(2):146–150. [PubMed: 18400116]
57.
Oddone EZ, Samsa G, Matchar DB. Global judgments versus decision-model-facilitated judgments: are experts internally consistent? Medical Decision Making. 1994 Jan-Mar;14(1):19–26. [erratum appears in Med Decis Making 1995 Jul-Sep;15(3):230] [PubMed: 8152353]
58.
Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000 May;17(5):479–500. [PubMed: 10977389]
59.
Claxton K, Eggington S, Ginnelly L, et al. A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence. Centre for Health Economics, University of York; 2005. [PubMed: 28481487]
60.
Cooper NJ, Sutton AJ, Ades AE, et al. Use of evidence in economic decision models: practical issues and methodological challenges. Health Economics. 2007 Dec;16(12):1277–1286. [PubMed: 18034447]
61.
Debicki D, Ferko N, Demarteau N, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine. 2008 Sep 15;26 Suppl 5:F16–28. [PubMed: 18992379]
62.
Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. International Journal of Technology Assessment in Health Care. 2005;21(2):165–171. [PubMed: 15921055]
63.
Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value in Health. 2009 Jun;12(4):409–418. [PubMed: 19900249]
64.
Duintjer Tebbens RJ, Thompson KM, Hunink MGM, et al. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Medical Decision Making. 2008 Mar-Apr;28(2):182–200. [PubMed: 18349438]
65.
Evans C, Crawford B. Expert judgement in pharmacoeconomic studies. Guidance and future use. Pharmacoeconomics. 2000 Jun;17(6):545–553. [PubMed: 10977393]
66.
Faissol DM, Griffin PM, Swann JL. Bias in Markov models of disease. Mathematical Biosciences. 2009 Aug;220(2):143–156. [PubMed: 19538974]
67.
Gallivan S. Challenging the role of calibration, validation and sensitivity analysis in relation to models of health care processes. Health Care Management Science. 2008 Jun;11(2):208–213. [PubMed: 18581827]
68.
Hughes D, Cowell W, Koncz T, et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value in Health. 2007 Nov-Dec;10(6):498–509. [PubMed: 17970932]
69.
Karnon J, Brennan A, Akehurst R. A critique and impact analysis of decision modeling assumptions. Medical Decision Making. 2007 Jul-Aug;27(4):491–499. [PubMed: 17761961]
70.
Lilford R, Girling A, Braunholtz D, et al. Cost-utility analysis when not everyone wants the treatment: modeling split-choice bias. Medical Decision Making. 2007 Jan-Feb;27(1):21–26. [PubMed: 17237449]
71.
McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics. 2000 May;17(5):501–513. [PubMed: 10977390]
72.
Stout NK, Knudsen AB, Kong CY, et al. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27(7):533–545. [PMC free article: PMC2787446] [PubMed: 19663525]
73.
Sun X, Faunce T. Decision-analytical modelling in health-care economic evaluations. European Journal of Health Economics. 2008 Nov;9(4):313–323. [PubMed: 17943332]
74.
Swan JS, Miksad RA. Measuring the quality-of-life effects of diagnostic and screening tests. Journal of the American College of Radiology. 2009 Aug;6(8):567–575. [PubMed: 19643385]
75.
Tavakoli M, Davies HT, Thomson R. Decision analysis in evidence-based decision making. Journal of Evaluation in Clinical Practice. 2000 May;6(2):111–120. [PubMed: 10970005]
76.
Trikalinos TA, Siebert U, Lau J. Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. Medical Decision Making. 2009 Sep-Oct;29(5):E22–29. [PubMed: 19734441]
77.
Bernstein SJ, Hofer TP, Meijler AP, et al. Setting standards for effectiveness: a comparison of expert panels and decision analysis. International Journal for Quality in Health Care. 1997 Aug;9(4):255–263. [PubMed: 9304424]
78.
Karnon J, Goyder E, Tappenden P, et al. A review and critique of modelling in prioritising and designing screening programmes. Health Technology Assessment. 2007 Dec;11(52):iii–iv. ix–xi, 1–145. [PubMed: 18031651]
79.
Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. European Journal of Cancer. 2006 Nov;42(17):2867–2875. [PubMed: 17023160]
80.
Luce BR. Policy implications of modeling the cost-effectiveness of health care technologies. Drug Info J. 1995;29:1469–1475.

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...